Phase 1 Safety Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors
by on Thursday, June 21st, 2012 | No Comments
Condition: Advanced Solid Tumors
Intervention: Drug: X-396
Sponsors: Xcovery Holding Company, LLC; Xcovery Holding Company, LLC
Recruiting – verified June 2012
Read more: Phase 1 Safety Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors